The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hemophilia Gene Therapy-Global Market Insights and Sales Trends 2025
Synopsis
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
The global Hemophilia Gene Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hemophilia Gene Therapy in various end use industries. The expanding demands from the Hemophilia A Gene Therapy and Hemophilia B Gene Therapy, are propelling Hemophilia Gene Therapy market. Hemophilia A, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hemophilia B segment is estimated at % CAGR for the next seven-year period.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemophilia Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemophilia Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemophilia Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemophilia Gene Therapy covered in this report include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc.
The global Hemophilia Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Global Hemophilia Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemophilia Gene Therapy market, Segment by Type:
Hemophilia A
Hemophilia B
Global Hemophilia Gene Therapy market, by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
The global Hemophilia Gene Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hemophilia Gene Therapy in various end use industries. The expanding demands from the Hemophilia A Gene Therapy and Hemophilia B Gene Therapy, are propelling Hemophilia Gene Therapy market. Hemophilia A, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hemophilia B segment is estimated at % CAGR for the next seven-year period.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemophilia Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemophilia Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemophilia Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemophilia Gene Therapy covered in this report include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc.
The global Hemophilia Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Global Hemophilia Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemophilia Gene Therapy market, Segment by Type:
Hemophilia A
Hemophilia B
Global Hemophilia Gene Therapy market, by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hemophilia Gene Therapy
1.1 Hemophilia Gene Therapy Market Overview
1.1.1 Hemophilia Gene Therapy Product Scope
1.1.2 Hemophilia Gene Therapy Market Status and Outlook
1.2 Global Hemophilia Gene Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hemophilia Gene Therapy Market Size by Region (2018-2029)
1.4 Global Hemophilia Gene Therapy Historic Market Size by Region (2018-2023)
1.5 Global Hemophilia Gene Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hemophilia Gene Therapy Market Size (2018-2029)
1.6.1 North America Hemophilia Gene Therapy Market Size (2018-2029)
1.6.2 Europe Hemophilia Gene Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Hemophilia Gene Therapy Market Size (2018-2029)
1.6.4 Latin America Hemophilia Gene Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Hemophilia Gene Therapy Market Size (2018-2029)
2 Hemophilia Gene Therapy Market by Type
2.1 Introduction
2.1.1 Hemophilia A
2.1.2 Hemophilia B
2.2 Global Hemophilia Gene Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hemophilia Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hemophilia Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hemophilia Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hemophilia Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hemophilia Gene Therapy Revenue Breakdown by Type (2018-2029)
3 Hemophilia Gene Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hemophilia A Gene Therapy
3.1.2 Hemophilia B Gene Therapy
3.2 Global Hemophilia Gene Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hemophilia Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hemophilia Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hemophilia Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hemophilia Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hemophilia Gene Therapy Revenue Breakdown by Application (2018-2029)
4 Hemophilia Gene Therapy Competition Analysis by Players
4.1 Global Hemophilia Gene Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hemophilia Gene Therapy as of 2022)
4.3 Date of Key Players Enter into Hemophilia Gene Therapy Market
4.4 Global Top Players Hemophilia Gene Therapy Headquarters and Area Served
4.5 Key Players Hemophilia Gene Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Hemophilia Gene Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Spark Therapeutics
5.1.1 Spark Therapeutics Profile
5.1.2 Spark Therapeutics Main Business
5.1.3 Spark Therapeutics Hemophilia Gene Therapy Products, Services and Solutions
5.1.4 Spark Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 Spark Therapeutics Recent Developments
5.2 Ultragenyx
5.2.1 Ultragenyx Profile
5.2.2 Ultragenyx Main Business
5.2.3 Ultragenyx Hemophilia Gene Therapy Products, Services and Solutions
5.2.4 Ultragenyx Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 Ultragenyx Recent Developments
5.3 Shire PLC
5.3.1 Shire PLC Profile
5.3.2 Shire PLC Main Business
5.3.3 Shire PLC Hemophilia Gene Therapy Products, Services and Solutions
5.3.4 Shire PLC Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Sangamo Therapeutics Recent Developments
5.4 Sangamo Therapeutics
5.4.1 Sangamo Therapeutics Profile
5.4.2 Sangamo Therapeutics Main Business
5.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Products, Services and Solutions
5.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Sangamo Therapeutics Recent Developments
5.5 Bioverativ
5.5.1 Bioverativ Profile
5.5.2 Bioverativ Main Business
5.5.3 Bioverativ Hemophilia Gene Therapy Products, Services and Solutions
5.5.4 Bioverativ Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 Bioverativ Recent Developments
5.6 BioMarin
5.6.1 BioMarin Profile
5.6.2 BioMarin Main Business
5.6.3 BioMarin Hemophilia Gene Therapy Products, Services and Solutions
5.6.4 BioMarin Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 BioMarin Recent Developments
5.7 uniQure
5.7.1 uniQure Profile
5.7.2 uniQure Main Business
5.7.3 uniQure Hemophilia Gene Therapy Products, Services and Solutions
5.7.4 uniQure Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 uniQure Recent Developments
5.8 Freeline Therapeutics
5.8.1 Freeline Therapeutics Profile
5.8.2 Freeline Therapeutics Main Business
5.8.3 Freeline Therapeutics Hemophilia Gene Therapy Products, Services and Solutions
5.8.4 Freeline Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 Freeline Therapeutics Recent Developments
6 North America
6.1 North America Hemophilia Gene Therapy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hemophilia Gene Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hemophilia Gene Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hemophilia Gene Therapy Market Dynamics
11.1 Hemophilia Gene Therapy Industry Trends
11.2 Hemophilia Gene Therapy Market Drivers
11.3 Hemophilia Gene Therapy Market Challenges
11.4 Hemophilia Gene Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
